Approval was based on results from the Phase IIIb FLOW trial, which demonstrated a 24% relative risk reduction in kidney ...

Nancy Ghattas, VP, US franchise head, imunno-oncology, gastrointestinal tumors, AstraZeneca, discusses the promising results ...

Effective February 10, 2025, Mamilli will assume global responsibility for the Informatics function for the Roche Group.

Paul Howe, chief commercial officer at Protega Pharma, discusses recent rule changes and how the industry is impacted by them ...

Essen Health Care announced that it is participating in the Guiding an Improved Dementia Experience (GUIDE) Model, an ...

Mark Genovese: Crohn’s disease is a chronic, inflammatory bowel disease associated with progressive bowel damage, disability, ...

Approval of Enhertu marks the first HER2-directed therapy indicated for adults with unresectable or metastatic HR-positive, ...

Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the ...

In the United States, the biomedical industry encounters numerous regulatory challenges in conducting nonclinical and ...

CStone, the drug’s developer, previously announced similar deals with various pharmaceutical companies to expand sugemalimab ...

Health In Tech announced new partnerships that it says will allow it to introduce a new self-funded health plan. 1 The ...

Priority review for Welireg is based on data from the Phase II LITESPARK-015 trial, which showed promising response rates in ...